Loading
Every dated change on the records linked to Relapsed and refractory acute lymphoblastic leukaemia in children, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
ORR 81%; 12-month OS 76%; 5-year OS 55%.
A milestone in how this cancer is treated.